Skip to main content

21-08-2018 | Juvenile idiopathic arthritis | Article

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

Kearsley-Fleet L et al. Rheumatology (Oxford) 2018: key262. doi: 10.1093/rheumatology/key262

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics